Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.51 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | GNPAT | O15228 | 1/20 | 0.40 |
| ▸ | ECE1 | P42892 | 2/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 4/20 | 0.38 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.38 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27793445 | 0.89 | NOD1 (0.56) | NOD1ACEDPP4FOLH1DPP8 | |
| SCHEMBL29674589 | 0.89 | NOD1 (0.56) | NOD1ACEDPP4FOLH1DPP8 | |
| SCHEMBL27793444 | 0.89 | NOD1 (0.56) | NOD1ACEDPP4FOLH1DPP8 | |
| SCHEMBL29406243 | 0.89 | NOD1 (0.56) | NOD1ACEDPP4FOLH1DPP8 | |
| SCHEMBL1711242 | 0.87 | FOLH1 (0.57) | NOD1FOLH1GNPAT | |
| SCHEMBL29563714 | 0.87 | FOLH1 (0.57) | NOD1FOLH1GNPAT | |
| SCHEMBL29368554 | 0.87 | FOLH1 (0.57) | NOD1FOLH1GNPAT | |
| SCHEMBL29511099 | 0.87 | FOLH1 (0.57) | NOD1FOLH1GNPAT | |
| SCHEMBL1711244 | 0.87 | FOLH1 (0.57) | NOD1FOLH1GNPAT | |
| SCHEMBL29405941 | 0.86 | FOLH1 (0.55) | NOD1FOLH1GNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220062371-A1 | LIGAND-DRUG-CONJUGATES AS SUBSTRATES FOR SELECTIVE CLEAVAGE BY THE EXOPEPTIDASE ACTIVITY OF CATHEPSIN B | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062371-A1 | LIGAND-DRUG-CONJUGATES AS SUBSTRATES FOR SELECTIVE CLEAVAGE BY THE EXOPEPTIDASE ACTIVITY OF CATHEPSIN B | CTSB, CTSE, CTSV | NOD1 3437/4885GABRR1 4118/4885ACE 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.